Category: Baricitinib

Baricitinib for patients with severe COVID-19—time to change the standard of care?

Posted on | Posted on John Murphy | Leave a Comment on Baricitinib for patients with severe COVID-19—time to change the standard of care?

AuthorsAlexander Supadya,c,d and Robert Zeiserb Lancet Respir Med. 2022 Feb 3doi: 10.1016/S2213-2600(22)00021-2 [Epub ahead of print]PMCID: PMC8813061PMID: 35123659 Mortality is high among patients with severe COVID-19 who require invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).1, 2 Therefore, further specific treatment options for these patients are urgently needed. Early in the COVID-19 pandemic, Janus kinase (JAK) inhibitors were identified as potential therapeutic agents […]

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds

Posted on | Posted on John Murphy | Leave a Comment on Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds

For hospitalized patients already taking other proven COVID-19 drugs, pill further reduces chance of death Authors: KAI KUPFERSCHMIDT 3 MAR 2022 1:20 PM Baricitinib, an oral drug that dampens an overactive immune system and is commonly used by people with rheumatoid arthritis, reduced hospitalized COVID-19 patients’ risk of dying by 13%, investigators of the world’s […]